[go: up one dir, main page]

FI944823L - Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa - Google Patents

Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa Download PDF

Info

Publication number
FI944823L
FI944823L FI944823A FI944823A FI944823L FI 944823 L FI944823 L FI 944823L FI 944823 A FI944823 A FI 944823A FI 944823 A FI944823 A FI 944823A FI 944823 L FI944823 L FI 944823L
Authority
FI
Finland
Prior art keywords
pharmaceuticals
preparation
galantamine derivatives
galantamine
derivatives
Prior art date
Application number
FI944823A
Other languages
English (en)
Swedish (sv)
Other versions
FI944823A0 (fi
FI108722B (fi
Inventor
Jr Raymond J Kosley
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of FI944823A0 publication Critical patent/FI944823A0/fi
Publication of FI944823L publication Critical patent/FI944823L/fi
Application granted granted Critical
Publication of FI108722B publication Critical patent/FI108722B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI944823A 1993-10-15 1994-10-13 Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin alkyylikarbonyyli- ja alkoksikarbonyylijohdannaisten valmistamiseksi FI108722B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/137,444 US6316439B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors
US13744493 1993-10-15

Publications (3)

Publication Number Publication Date
FI944823A0 FI944823A0 (fi) 1994-10-13
FI944823L true FI944823L (fi) 1995-04-16
FI108722B FI108722B (fi) 2002-03-15

Family

ID=22477461

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944823A FI108722B (fi) 1993-10-15 1994-10-13 Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin alkyylikarbonyyli- ja alkoksikarbonyylijohdannaisten valmistamiseksi

Country Status (23)

Country Link
US (1) US6316439B1 (fi)
EP (1) EP0649846B1 (fi)
JP (1) JP2664343B2 (fi)
KR (1) KR100227957B1 (fi)
CN (1) CN1039910C (fi)
AT (1) ATE211474T1 (fi)
AU (1) AU696170B2 (fi)
CA (1) CA2118172C (fi)
CZ (1) CZ283731B6 (fi)
DE (1) DE69429570T2 (fi)
DK (1) DK0649846T3 (fi)
EG (1) EG20726A (fi)
ES (1) ES2170759T3 (fi)
FI (1) FI108722B (fi)
IL (1) IL111275A (fi)
NO (1) NO307464B1 (fi)
NZ (1) NZ264682A (fi)
PL (1) PL177549B1 (fi)
PT (1) PT649846E (fi)
RO (1) RO114134B1 (fi)
RU (1) RU2109743C1 (fi)
TW (1) TW289754B (fi)
ZA (1) ZA948061B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU780012B2 (en) * 1999-12-10 2005-02-24 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
WO2002088138A1 (en) * 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
AU2005322611A1 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of Alzheimer's disease
US8632800B2 (en) * 2005-05-13 2014-01-21 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
PL2137192T3 (pl) 2008-04-14 2014-07-31 Neurodyn Life Sciences Inc Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi
US20120184532A1 (en) * 2009-07-23 2012-07-19 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) * 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
WO1992020327A1 (en) 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
IL111275A (en) 2003-01-12
FI944823A0 (fi) 1994-10-13
CN1108657A (zh) 1995-09-20
AU7581394A (en) 1995-05-04
DE69429570T2 (de) 2002-08-29
CA2118172C (en) 2000-01-04
IL111275A0 (en) 1994-12-29
NO943895L (no) 1995-04-18
TW289754B (fi) 1996-11-01
JP2664343B2 (ja) 1997-10-15
CN1039910C (zh) 1998-09-23
NO943895D0 (no) 1994-10-14
FI108722B (fi) 2002-03-15
RU2109743C1 (ru) 1998-04-27
KR950011445A (ko) 1995-05-15
PL177549B1 (pl) 1999-12-31
AU696170B2 (en) 1998-09-03
JPH07188239A (ja) 1995-07-25
US6316439B1 (en) 2001-11-13
RU94036745A (ru) 1996-12-10
ATE211474T1 (de) 2002-01-15
EG20726A (en) 1999-12-29
PL305457A1 (en) 1995-04-18
CZ283731B6 (cs) 1998-06-17
CZ254594A3 (en) 1995-07-12
ES2170759T3 (es) 2002-08-16
CA2118172A1 (en) 1995-04-16
KR100227957B1 (ko) 1999-11-01
DE69429570D1 (de) 2002-02-07
NZ264682A (en) 1995-07-26
DK0649846T3 (da) 2002-04-15
EP0649846A1 (en) 1995-04-26
EP0649846B1 (en) 2002-01-02
ZA948061B (en) 1995-06-06
NO307464B1 (no) 2000-04-10
RO114134B1 (ro) 1999-01-29
PT649846E (pt) 2002-06-28

Similar Documents

Publication Publication Date Title
FI944821L (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI944822L (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI955913A7 (fi) Uudet erytromysiinijohdannaiset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
FI941137A7 (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI955140L (fi) Uusia kinoksaliinidionijohdannaisia, niiden valmistus ja käyttö lääkkeissä
FI931499A7 (fi) Syklopeptidit, menetelmä niiden valmistamiseksi ja niiden käyttö lääke aineina
EE9600172A (et) Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid
FI951468L (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
FI935465L (fi) Termoplastinen koostumus, menetelmä sen valmistamiseksi ja sen käyttö
FI944823L (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI944600L (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
FI931336A7 (fi) Polyhydroksimetyleenijohdannaisia sisältäviä lääkkeitä, menetelmä niiden valmistamiseksi ja käyttämiseksi
FI942499L (fi) Indolijohdannainen, menetelmä sen valmistamiseksi ja sen lääkekäyttö
FI931414A7 (fi) Imidatsolijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
EE04371B1 (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
FI911615A7 (fi) Uusia 4-kinolyyli-dihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI931232L (fi) Makeutusaine, menetelmä sen valmistamiseksi ja sen käyttö
FI951631L (fi) Substituoituja kynureniinejä, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeinä
FI953956L (fi) 2,3-rengaskondensoidut 1,4-dihydropyridiinit, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
FI933544A7 (fi) Tiadiatsiinikarboksamidijohdannaiset, menetelmät niiden valmistamiseks i ja lääkkeet
FI941911L (fi) Kondensoidut kinolyylidihydropyridiinit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI953532A7 (fi) Nitroglyserolia sisältävä laastari, menetelmä sen valmistamiseksi ja s en käyttö
FI955679L (fi) Piperidiinijohdannaisia, niiden valmistus ja käyttö
FI941912L (fi) 3-kinolyylillä substituoidut dihydropyridiinit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI902901A7 (fi) Dibentsoli/1,5/dioksosiini-5-oni-johdannaisia, niiden käyttö lääkeaineissa ja menetelmä niiden valmistamiseksi

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: HOECHST MARION ROUSSEL, INC.

PC Transfer of assignment of patent

Owner name: AVENTISUB II INC.

Free format text: AVENTISUB II INC.

MA Patent expired